Trevi Therapeutic…
USUSDTrevi Therapeutics Inc (US:TRVI) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 1. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- trevitherapeutics.com
- Investoru Attiecības
- ir.trevitherapeutics.com/
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā Mītne
- NEW HAVEN, United States
- Izpilddirektors
- Jennifer L. Good
- Darbinieki
- 34
- Apgrozībā Esošās Akcijas
- 142.48 milj. uz 2026-07-31
- Brīvā Apgrozība
- 118.32 milj.
- Tirgus Kapitalizācija
- 1.92 mljrd. USD
- Iekšējās Personas
- 0.63%
- Institucionālie Investori
- 107.73%
- Nozare (SIC)
- Pharmaceutical Preparations
- P/E
- zaudējumi
- FCF
- −52.9 milj. USD
- Parāds
- ?
- Peļņa un FCF — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
- NAV
Apraksts
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Biržas un Tikeri
| Birža | Tikeris | Valūta | Cena | Veids |
|---|---|---|---|---|
| US USA Stocks | TRVI | USD | 12.11 +0.41% | parastās akcijas |
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| NEA Management Company,… | 9.28% | 13.22 milj. | 2026-06-30 |
| FMR, LLC | 8.82% | 12.56 milj. | 2026-06-30 |
| Blackrock Inc. | 7.83% | 11.16 milj. | 2026-06-30 |
| Frazier Life Sciences Ma… | 6.98% | 9.94 milj. | 2026-06-30 |
| Wellington Management Gr… | 3.99% | 5.68 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 3.88% | 5.53 milj. | 2026-06-30 |
| Vivo Capital, LLC | 3.58% | 5.09 milj. | 2026-06-30 |
| Woodline Partners LP | 2.86% | 4.08 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.84% | 4.05 milj. | 2026-06-30 |
| Vestal Point Capital, LP | 2.18% | 3.1 milj. | 2026-06-30 |
| MPM Bioimpact LLC | 2.16% | 3.07 milj. | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.91% | 2.72 milj. | 2026-08-31 |
| MUTUAL FUND SERIES TRUST… | 1.87% | 2.66 milj. | 2026-06-30 |
| Fidelity Select Portfoli… | 1.67% | 2.37 milj. | 2026-07-31 |
| Fidelity Securities Fund… | 1.37% | 1.95 milj. | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 1.35 milj. | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.82% | 1.17 milj. | 2026-07-31 |
| Fidelity Mt. Vernon Stre… | 0.73% | 1.04 milj. | 2026-07-31 |
| AB CAP FUND, INC.-AB Sma… | 0.72% | 1.03 milj. | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.7% | 996 857 | 2026-08-31 |
| SCIASCIA THOMAS R (Offic… | ≈0.16% | 221 373 | 2025-03-25 |
| GOOD JENNIFER L (Chief E… | ≈0.15% | 213 313 | 2025-03-21 |
| BASKETT FOREST (Benefici… | — | — | 2025-04-17 |
| BEHBAHANI ALI (Beneficia… | — | — | 2025-04-17 |
| CHANG CARMEN (Beneficial… | — | — | 2025-04-17 |
| FLORENCE ANTHONY A JR (B… | — | — | 2025-04-17 |
| MAKHZOUMI MOHAMAD (Benef… | — | — | 2025-04-17 |
| NEW ENTERPRISE ASSOCIATE… | — | — | 2025-04-17 |
| SANDELL SCOTT D (Benefic… | — | — | 2025-04-17 |
| WALKER PAUL EDWARD (Bene… | — | — | 2025-04-17 |
Pieslēdzies ar Google